ALPORT SYNDROME
Clinical trials for ALPORT SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ALPORT SYNDROME trials appear
Sign up with your email to follow new studies for ALPORT SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to reduce kidney damage in rare diseases
Disease control CompletedThis study tested a new drug called R3R01 in 43 people with two rare kidney diseases: Alport syndrome and focal segmental glomerulosclerosis (FSGS). The goal was to see if the drug is safe and can lower protein in the urine, a sign of kidney damage. Participants had uncontrolled …
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated May 26, 2026 11:42 UTC
-
New drug shows promise in slowing kidney damage for alport syndrome patients
Disease control CompletedThis study tested a drug called setanaxib in 20 people with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if adding setanaxib to standard care is safe and helps preserve kidney function by reducing protein in urine. Participants took either setana…
Matched conditions: ALPORT SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated May 26, 2026 11:42 UTC
-
Experimental drug targets genetic kidney disease in small trial
Disease control CompletedThis early study tested a drug called ELX-02 in 3 people with Alport syndrome, a genetic kidney disease. The goal was to see if the drug is safe and if it can reduce protein in the urine, a sign of kidney damage. Participants received daily injections for 8 weeks and were monitor…
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug shows promise for slowing kidney damage in alport syndrome
Disease control CompletedThis study tested a drug called vonafexor in 26 people with Alport syndrome, a genetic condition that harms the kidneys. The goal was to see if the drug is safe and can help protect kidney function. Researchers measured side effects and changes in kidney health over time.
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Alport syndrome registry aims to fuel future treatments
Knowledge-focused CompletedThis study created a registry of 655 people with Alport syndrome to collect health information over time. The goal is to better understand the disease and lay the groundwork for future treatment studies. Participants provided medical data and family history, but no experimental t…
Matched conditions: ALPORT SYNDROME
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated May 26, 2026 11:28 UTC